Mediwound vs Proqr Therapeutics
Mediwound and Proqr Therapeutics are similar in size: $17.0m and $18.0m of revenue in their latest fiscal years. Proqr Therapeutics grew faster (-12.1% against -16.1%). Mediwound kept more of each dollar of sales as profit: a net margin of -140.8% against -265.2%. Mediwound carries less debt relative to equity (0.0% against 9.9%).
| Latest fiscal year | MediwoundMDWD, 2025 | Proqr TherapeuticsPRQR, 2025 |
|---|---|---|
| Revenue | $17.0m | $18.0m |
| Revenue growth | -16.1% | -12.1% |
| Net income | −$23.9m | −$47.7m |
| Operating margin | -149.0% | -273.1% |
| Net margin | -140.8% | -265.2% |
| Return on equity | -63.9% | -63.8% |
| Free cash flow | −$21.6m | −$60.8m |
| Cash | $4.8m | $108m |
| Total debt | $0 | $5.7m |
| Debt to equity | 0.0% | 9.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $172m | $144m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 7 buys, 4 sales | 5 buys, 0 sales |